抽象的な
Future prospects for DLBCL treatment: Combination of WEE1 inhibitors with CHOP and radiation therapy
Tom van Meerten, Mathilde Rikje Willemijn de Jong, Lydia Visser
Diffuse large B-cell lymphoma (DLBCL) is the most aggressive and common form of non-Hodgkin lymphoma. DLBCL arises during B-cell development in the germinal center reaction as a result of high levels of genomic rearrangements to create high affinity B-cell receptors. Therefore, an important hallmark of DLBCL is the high levels of genomic instability; DNA damage and DNA damage response proteins
免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。